# OnCo record polatuzumab-vedotin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/polatuzumab-vedotin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "polatuzumab-vedotin" ;
  schema:name "Polatuzumab vedotin"@en ;
  schema:description "Polatuzumab vedotin is an ADC against CD79b that, swapped into the classic R-CHOP regimen, became the first improvement on frontline lymphoma therapy in twenty years."@en ;
  schema:url <https://onco.cc/drugs/polatuzumab-vedotin/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Polatuzumab_vedotin> ;
  owl:sameAs <http://www.wikidata.org/entity/Q19946115> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Polatuzumab%20vedotin>, <https://doi.org/10.1038/nature08638> ;
  onco:status "approved" ;
  onco:modality "ADC" ;
  schema:alternateName "Polivy" ;
  onco:approval "US 2019: Relapsed/refractory DLBCL with bendamustine-rituximab after ≥2 lines (accelerated)", "US 2023: Untreated DLBCL, IPI ≥2, with R-CHP (Pola-R-CHP)" ;
  onco:acceleratedApproval "US 2019-06-10: In combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies." ;
  onco:acceleratedApprovalConfirmed "US 2023-04-19: In combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies." ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/cd79b/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:terms <https://onco.cc/terms/payload/>, <https://onco.cc/terms/bystander-effect/> ;
  onco:trials <https://onco.cc/trials/polarix/>, <https://onco.cc/trials/nct04844866/>, <https://onco.cc/trials/nct03671018/>, <https://onco.cc/trials/nct03533283/>, <https://onco.cc/trials/nct06890884/> .